BPMC - Blueprint Medicines Corporation
84.00 0.00 (0.00%)
After hours: 5:22PM EDT
| Previous Close | 82.64 |
| Open | 83.07 |
| Bid | 83.45 x 800 |
| Ask | 92.00 x 1000 |
| Day's Range | 82.88 - 85.50 |
| 52 Week Range | 44.58 - 105.00 |
| Volume | 355,399 |
| Avg. Volume | 376,320 |
| Market Cap | 3.704B |
| Beta (3Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.39 |
| Earnings Date | Apr 30, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 100.29 |
- PR Newswire•14 days ago
Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
CAMBRIDGE, Mass. , March 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, ...
- GlobeNewswire•19 days ago
Market Trends Toward New Normal in ITT, Palo Alto Networks, Enterprise Products Partners, Blueprint Medicines, Lincoln Electric, and NewMarket — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of BPMC earnings conference call or presentation 26-Feb-19 1:30pm GMT
Q4 2018 Blueprint Medicines Corp Earnings Call
Motley Fool•21 days agoBlueprint Medicines Corp (BPMC) Q4 2018 Earnings Conference Call Transcript
BPMC earnings call for the period ending December 31, 2018.
- PR Newswire•22 days ago
Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
-- Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter -- -- BLU-667 receives Breakthrough Therapy Designation for the treatment of RET ...
- Motley Fool•26 days ago
3 Top Healthcare Stocks to Buy in February
Canopy Growth Corporation, MyoKardia, and Blueprint Medicines are all outstanding healthcare picks this month.
- PR Newswire•28 days ago
Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
CAMBRIDGE, Mass. , Feb. 19, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced ...
- Zacks•last month
Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Markit•last month
See what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Blueprint Medicines Corp NASDAQ/NGS:BPMCView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BPMC totaled $2.45 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- PR Newswire•last month
Blueprint Medicines to Present at Upcoming Investor Conferences in February
CAMBRIDGE, Mass. , Feb. 7, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, ...
- ACCESSWIRE•2 months ago
Three Companies Using AI and Innovation to Lead Healthcare Sector
HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence. In fact, AI is quickly proving it can spot warning signs of disease before we're even aware of it ourselves. "Artificial intelligence could also use the way we look to help us predict future disease.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT
Q3 2018 Blueprint Medicines Corp Earnings Call
- Investor's Business Daily•2 months ago
Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table
Pharma giant Eli Lilly put together its winning bid for Loxo Oncology in just 10 days ahead of the J.P. Morgan Healthcare Conference, according to documents filed Thursday with the SEC.
- Motley Fool•2 months ago
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
- MarketWatch•2 months ago
Cancer stocks heat up after third big merger in the past month
The third multibillion-dollar buyout of cancer-treatment developers in the past month was a charm for the shares of targeted oncology companies, as Leerink analyst Andrew Berens said Eli Lilly’s deal to buy Loxo Oncology validated the “significant value and interest” in the sector.
- PR Newswire•2 months ago
Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals
-- Top-line avapritinib data support planned NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST in first half 2019 -- -- Registration-enabling trials for avapritinib in advanced and indolent systemic ...
- GlobeNewswire•3 months ago
Analysis: Positioning to Benefit within Quidel, Granite Construction, FireEye, Consolidated Edison, EnPro Industries, and Blueprint Medicines — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Dec. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Insider Monkey•3 months ago
Is Blueprint Medicines Corporation (BPMC) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
- Simply Wall St.•3 months ago
Is Blueprint Medicines Corporation’s (NASDAQ:BPMC) CEO Overpaid Relative To Its Peers?
In 2014 Jeff Albers was appointed CEO of Blueprint Medicines Corporation (NASDAQ:BPMC). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll Read More...
- PR Newswire•4 months ago
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
- 83% overall response rate, with evidence of deepening of response over time - - Median duration of response not reached; 12-month duration of response rate of 76% - - Statistically significant improvements ...
